Please assess the completion status of the following clinical trial:

Trial Title: Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* First time kidney transplant recipients who receives a kidney from a cadaveric, living related or living unrelated donor~* Age greater than 18 years and less than 75 years~* Caucasian recipients~* Patients with current low panel reactive antibody (PRA) levels (\<10%)~* Patients with signed and dated informed consent~* Women of childbearing potential must have a negative pregnancy test at baseline and agree to use a medically acceptable method of contraception throughout the treatment period.~Exclusion Criteria:~* Other than Caucasian ethnicity~* Patients with HIV+ or~* Patients with HbsAg+ or Hepatitis C positive~* Patients with a history of malignancy in the past 5 years~* Patients with active systemic or localized major infection~* Patients with a history of chronic steroid use for other diseases

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Prednisone Withdrawal (Type: EXPERIMENTAL): Participants randomized to the prednisone withdrawal group, received 4 medications to prevent rejection. Thymoglobulin (rabbit antithymocyte globulin) was given intravenously in the operating room at the time of transplant. Subsequent intravenous doses were administered to participants an inpatient or outpatient for a total of 3 to 5 doses. Participants also began taking Prograf (tacrolimus) and CellCept (mycophenolate mofetil)orally within 24 hours of transplant and continued indefinitely. The steroids were initially given in the operating room intravenously at time of transplant as Solu-medrol (methylprednisolone)and were then switched to daily oral prednisone doses. The participant's dose of prednisone was rapidly decreased until it was completely eliminated by day 6 post-transplant.
- Prednisone Maintenance (Type: ACTIVE_COMPARATOR): Participants randomized to the prednisone maintenance group, received 4 medications to prevent rejection. Thymoglobulin (rabbit antithymocyte globulin) was initiated intravenously in the operating room at the time of transplant. Subsequent intravenous doses were administered an inpatient or outpatient for a total of 3 to 5 doses. Participants began taking Prograf (tacrolimus) and CellCept (mycophenolate mofetil)orally within 24 hours of transplant and continued on them indefinitely. The steroids were initially given intravenously in the operating room at time of transplant as Solu-medrol (methylprednisolone) and were then switched to daily oral prednisone tablets. Participants remained on all drugs according to their doctor's standard of care, and the prednisone was not be eliminated.

Based on this trial design, predict the completion outcome and termination type (if applicable).